Halia Therapeutics, a US-based clinical-stage biopharmaceutical company, announced on Thursday that it has named Lisa Shamon, PhD as its new vice president Regulatory Affairs and Xianne Penny, PhD, NREMT as its new senior medical director.

Dr Shamon has more than 20 years of experience in the pharmaceutical biotechnology industry having headed multiple programs via early- through late-stage development. She has expertise in regulatory strategies and global interactions for oncology and other therapeutic areas, which includes rare diseases. She has served in various regulatory affairs positions at several companies, including Alza Corporation, Exelixis, Inc., Aeglea BioTherapeutics, FivePrime Therapeutics, Inc., and Amgen, Inc.

Dr Penny is an immuno-oncology specialist and has served for many years of her career in research in this field. She has served in roles of senior principal clinical immunologist at Amgen.